Oncology Today with Dr Neil Love

59:59

Gastroesophageal Cancers — Year in Review Series on...

Oncology Today with Dr Neil Love ·

2026/08/19

Featuring perspectives from Dr David H Ilson and Dr Kohei Shitara, including the following topics:Introduction (00:00)Biomarker Evaluation in Localized and Metastatic Disease (1:49)Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Ilson (7:37)Other Available Therapeutic Approaches — Dr Shitara (33:22)CME information and select publications

en

01:30:11

Genitourinary Cancers — Reviewing Key Presentations...

Oncology Today with Dr Neil Love ·

2026/08/19

Featuring perspectives from Dr Rahul Aggarwal, Dr Matthew D Galsky and Dr Tian Zhang, including the following topics:Introduction: Welcome GU Oncology Fellows! (0:00)Prostate Cancer — Dr Aggarwal (12:48)Urothelial Bladder Cancer — Dr Galsky (45:01)Renal Cell Carcinoma — Dr Zhang (1:10:52)CME information and select publications

en

25:48

Metastatic Bladder Cancer — Rapid Case Review Issue 6

Oncology Today with Dr Neil Love ·

2026/08/18

Featuring perspectives from Prof Yohann Loriot, including the following topics:Case: A man in his early 80s with metastatic urothelial bladder cancer (mUBC) receives enfortumab vedotin (EV)/pembrolizumab but experiences immune-related adverse events requiring steroids and then develops neuropathy due to EV — Nazli Dizman, MD (0:00)Case: A man in his early 70s with diabetes who received adjuvant nivolumab for FGFR3-mutant metastatic urothelial cancer receives first-line EV monotherapy and experiences

en

01:27:50

For Oncology Nurses: Oral Selective Estrogen Receptor...

Oncology Today with Dr Neil Love ·

2026/08/18

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:Introduction (0:00)Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)Practical Considerations with Oral SERDs (15:43)Potential Role of Combination Approaches with Oral SERDs (26:33)Gastrointestinal Adverse Events Documented with Oral SERDs (38:19)Potential Role

en

28:40

Metastatic Bladder Cancer — Rapid Case Review Issue 5

Oncology Today with Dr Neil Love ·

2026/08/17

Featuring perspectives from Prof Yohann Loriot, including the following topics:Case: A man in his early 80s with Parkinson disease and a history of renal transplant presents with metastatic urothelial bladder cancer (UBC) and receives first-line enfortumab vedotin (EV) with a good response but develops neuropathy and skin toxicity — Jacqueline T Brown, MD (0:00)Case: A man in his early 90s with excellent PS and locally advanced UBC receives EV and pembrolizumab as palliative treatment, develops

en

57:45

Multiple Myeloma — Year in Review Series on Relevant...

Oncology Today with Dr Neil Love ·

2026/08/17

Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics:Introduction (00:00)Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47)Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34)Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15)ASCO and EHA 2026 (46:37)CME information and select publications

en

20:22

Non-Muscle-Invasive and Muscle-Invasive Bladder...

Oncology Today with Dr Neil Love ·

2026/08/15

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:Case: A woman in her late 60s with T3N0 upper tract urothelial carcinoma that was resected has no evidence of disease on imaging, receives negative circulating tumor DNA results and elects observation instead of adjuvant treatment (0:00)Case: A man in his late 70s with PD-L1-negative high-grade muscle-invasive bladder cancer who is

en

22:47

Non-Muscle-Invasive and Muscle-Invasive Bladder...

Oncology Today with Dr Neil Love ·

2026/08/14

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:Case: A healthy man in his early 70s who received several different lines of therapy for non-muscle-invasive bladder cancer (NMIBC), wants to avoid radical cystectomy and does not want pembrolizumab (0:00)Case: A man in his late 70s with newly diagnosed NMIBC with carcinoma in situ (11:20)CME information and select publications

en

01:59:30

Non-Hodgkin Lymphoma — Proceedings from a Session...

Oncology Today with Dr Neil Love ·

2026/08/13

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics:Introduction (0:00)Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16)Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21)CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Abramson (51:10)Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma

en

01:59:07

Prostate Cancer — Proceedings from a Session Held in...

Oncology Today with Dr Neil Love ·

2026/08/12

Featuring perspectives from Dr Wassim Abida, Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Rana R McKay, moderated by Dr McKay, including the following topics:Introduction (0:00)Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Antonarakis (2:42)Current and Future Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Aggarwal (26:23)Current and Future Role of Regimens Combining PARP Inhibitors and Androgen Receptor (AR) Pathway Inhibitors in

en

57:46

Myelofibrosis — Proceedings from a Webinar Held in...

Oncology Today with Dr Neil Love ·

2026/08/11

Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics:Introduction (0:00)The Biopathophysiology of Myelofibrosis (MF) (2:19)Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49)Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00)Upcoming at European Hematology Association (EHA) 2026 (49:22)CME information and select publications

en

01:29:56

For Oncology Nurses: Targeting the PI3K/AKT/mTOR...

Oncology Today with Dr Neil Love ·

2026/08/10

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:Introduction (00:00)Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00)Strategies to Prevent and Manage Hyperglycemia (27:02)Clinical Utility of Capivasertib for HR-Positive mBC (38:09)Mitigation and Management of Gastrointestinal

en

01:59:01

Small Cell Lung Cancer — Proceedings from a Session...

Oncology Today with Dr Neil Love ·

2026/08/07

Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics:Introduction (0:00)Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17)Management of Relapsed/Refractory SCLC — Dr Paz-Ares (33:24)Ongoing Investigation and Potential Role of Antibody-Drug Conjugates in SCLC — Dr Chiang (1:02:28)Management of Limited-Stage SCLC — Dr Ganti

en

01:28:55

Gastroesophageal Cancers — Proceedings from a Session...

Oncology Today with Dr Neil Love ·

2026/08/06

Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics:Introduction (0:00)HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08)Targeting CLDN18.2 in Advanced Gastroesophageal Cancers — Dr Shah (30:54)Available Immunotherapeutic Strategies for Advanced Gastroesophageal Cancers — Dr Janjigian (1:01:39)CME information and select publications

en

02:00:04

Chronic Lymphocytic Leukemia — Proceedings from a...

Oncology Today with Dr Neil Love ·

2026/08/05

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:Introduction (0:00)Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24)Optimal Management of Adverse Events with BTK

en

59:01

Non-Small Cell Lung Cancer — Year in Review Series on...

Oncology Today with Dr Neil Love ·

2026/08/03

Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics:Introduction: Relative Impact of Targeted Treatment (00:00)HER2 Alterations (8:04)KRAS Mutations (24:25)MET Overexpression (30:34)ALK Fusions (32:34)ROS1 Fusions (42:36)RET Fusions (52:00)CME information and select publications

en

01:26:43

For Oncology Nurses: Relapsed/Refractory Multiple...

Oncology Today with Dr Neil Love ·

2026/08/03

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:Introduction (0:00)Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)Utility of Belantamab Mafodotin in R/R MM (49:29)Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)CME information and select publications

en

01:31:15

TROP2- and CDH6-Directed ADCs in Gynecologic Cancers...

Oncology Today with Dr Neil Love ·

2026/08/01

Featuring an interview with Dr Ramez Eskander, including the following topics:Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00)Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53)Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58)Current and investigational targets of ADCs in gynecologic cancers

en

30:11

HER2-Altered Non-Small Cell Lung Cancer — 5-Minute...

Oncology Today with Dr Neil Love ·

2026/07/30

Featuring perspectives from Dr Joshua K Sabari, including the following topics:Jänne PA et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02 — A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J Thorac Oncol 2025;20(12):1814-28. (0:00)Heymach JV et al. Circulating tumor DNA (ctDNA) analysis following zongertinib treatment (tx) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-mutant

en

16:53

HER2-Altered Non-Small Cell Lung Cancer — 5-Minute...

Oncology Today with Dr Neil Love ·

2026/07/30

Featuring perspectives from Dr Joshua K Sabari, including the following topics:Heymach JV et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med 2025;392(23):2321-33. (0:00)Popat S et al. Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG-1. ESMO 2025;Abstract LBA74. (5:25)Le X et al. Sevabertinib in advanced HER2-mutant non-small cell lung cancer. N Engl J Med 2025;393(18):1819-32. (12:37)CME information and select

en

All Episodes

Similar Podcasts

The Deep Dive Lab: Unraveling Materials Science

Son Hoang

New Books in Political Science

New Books Network

Station 151

Pale Matter | Realm

Beyond the Divide

Koala Moon

StarTalk with Neil deGrasse Tyson

Neil deGrasse Tyson